Literature DB >> 6474522

[Radiotherapy in endocrine ophthalmopathy--evaluation of 56 cases].

D Uhlenbrock, H J Fischer, R Rohwerder.   

Abstract

The authors present the radiotherapeutic results achieved in 56 patients with endocrine ophthalmopathy, 15 out of them with severe, so-called malignant course. All patients were irradiated conventionally with small doses between 3 and 10 Gy at the surface. For this purpose, a deep therapy unit with 250 kV was used. The X-ray irradiation produced an improvement in 62% of the cases; the separate evaluation of cases with malignant course showed an improvement in nine cases. Thus the results produced by this method are as good as those of high doses, the greater possibilities in case of recurrence, however, are to be considered as an advantage. The irradiation should be applied early, and the simultaneous administration of a cortisone preparation is preferred by our team.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6474522

Source DB:  PubMed          Journal:  Strahlentherapie        ISSN: 0039-2073


  4 in total

1.  DEGRO practical guidelines for the radiotherapy of non-malignant disorders - Part IV: Symptomatic functional disorders.

Authors:  Gabriele Reinartz; Hans Theodor Eich; Fabian Pohl
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

Review 2.  Immunosuppressant therapy of thyroid eye disease.

Authors:  G Kahaly; J Beyer
Journal:  Klin Wochenschr       Date:  1988-11-01

Review 3.  Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines.

Authors:  M H Seegenschmiedt; O Micke; R Muecke
Journal:  Br J Radiol       Date:  2015-05-08       Impact factor: 3.039

4.  [Endocrine orbitopathy: comparison of the long-term result and classification after radiotherapy].

Authors:  M H Seegenschmiedt; L Keilholz; G Gusek-Schneider; S Barth; J Hensen; F Wolf; G O Naumann; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-09       Impact factor: 4.033

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.